Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms

Biochem Biophys Res Commun. 1999 Nov 19;265(2):563-8. doi: 10.1006/bbrc.1999.1721.

Abstract

MMP3, MMP9, and PAI-1 are present at increased levels in abdominal aortic aneurysms (AAAs). The promoters of these genes contain polymorphisms, with alleles that exhibit different transcriptional activities in vitro. Association studies were performed using these polymorphisms and DNA isolated from 47 AAA patients, 57 intracranial aneurysm (IA) patients, and 174 controls, all from Finland. PAI-1 and MMP9 genotypes did not associate with aneurysms. The frequency of the 5A MMP3 allele was somewhat higher in the AAA than that in the control group (P = 0.0609 after Bonferroni correction), whereas the MMP3 allele frequencies in the IA group did not differ from those of the controls (P = 0.9667). These findings suggest that the transcriptionally more active 5A MMP3 allele might be a genetic risk factor for AAA among Finns. They are in agreement with previous studies demonstrating higher level of MMP3 expression in AAA than in control tissues.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • Animals
  • Aortic Aneurysm, Abdominal / enzymology*
  • Aortic Aneurysm, Abdominal / genetics*
  • Base Sequence
  • Case-Control Studies
  • DNA Primers / genetics
  • Female
  • Finland
  • Gene Frequency
  • Genotype
  • Humans
  • Intracranial Aneurysm / enzymology*
  • Intracranial Aneurysm / genetics*
  • Male
  • Matrix Metalloproteinase 3 / genetics*
  • Matrix Metalloproteinase 9 / genetics*
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / genetics*
  • Polymorphism, Genetic
  • Risk Factors

Substances

  • DNA Primers
  • Plasminogen Activator Inhibitor 1
  • Matrix Metalloproteinase 3
  • Matrix Metalloproteinase 9